Research Publications

Back

Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice


Caminschi, I; Vremec, D; Ahmet, F; Lahoud, MH; Villadangos, JA; Murphy, KM; Heath, WR; Shortman, K
2012-02
MOLECULAR IMMUNOLOGY
Journal Article
50
1-2
9-17
Injection of antigens coupled to antibodies against the dendritic cell (DC) surface molecule Clec9A has been shown to produce strongly enhanced antibody responses even without co-administration of adjuvants, via antigen presentation by DC on MHC class II and consequent production of follicular helper T cells. A series of mutant mice were tested to determine the DC subtypes responsible for this MHC II presentation of targeted antigen, compared to presentation of antigen on MHC I. A new clec9A null mouse was developed; these mice did not give enhanced antibody production, confirming the response was dependent on Clec9A-expressing DC. However targeting of antigen to Clec9A in batf3 null mice produced enhanced antibody responses despite the marked reduction in CD8(+) DC, the major Clec9A-expressing DC subtype. This was shown to be dependent on efficient MHC II presentation by minor Clec9A-expressing DC subtypes in the environment of the Batf3(-/-) mice, namely early cells of the CD8 DC lineage and the plasmacytoid-related CD8(+) DC subset, but not by plasmacytoid cells themselves. However in normal mice most MHC II presentation of the Clec9A-targeted antigen was by the major CD8(+) DC population, the DC also responsible for presentation on MHC I. (c) 2011 Elsevier Ltd. All rights reserved.
PERGAMON-ELSEVIER SCIENCE LTD
C-TYPE LECTIN; ANTIGEN CROSS-PRESENTATION; IN-VIVO; T-CELLS; CD8(+); SUBSET; EXPRESSION; RECEPTOR; SPLEEN; CLEC9A
Immunology
10.1016/j.molimm.2011.11.008
Copyright © 2013 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.

Back
Creation Date 2012-02-01 12:00:00